Ta strona została przetłumaczona automatycznie i dokładność tłumaczenia nie jest gwarantowana. Proszę odnieść się do angielska wersja za tekst źródłowy.

Comparison of VxWave and Standard Ultrasound Measurements of Blood Vessels in the Arm

29 października 2026 zaktualizowane przez: Vexev Pty Ltd

The VxWave Ultrasound Imaging System Upper Limb Clinical Performance Trial

This study compares blood-vessel measurements obtained with the VxWave Ultrasound Imaging System and a standard ultrasound system operated by a qualified sonographer. Adults aged 21 years or older undergo scanning of the same arm with both systems at one study visit. The researchers compare vessel diameter and blood-flow velocity at three specified locations in the upper arm and forearm. They also assess scan completion, scanning time, participant comfort, device deficiencies and adverse events. A subset undergoes a repeat standard ultrasound scan to assess the repeatability of the reference measurements.

Przegląd badań

Szczegółowy opis

This is an interventional, single-cohort, within-participant paired method-comparison study. Every participant undergoes VxWave scanning first, followed by Philips Lumify scanning of the same arm by a qualified vascular sonographer in a separate room. Three locations are examined: the brachial artery immediately proximal and immediately distal to the midpoint between the elbow crease and axillary fold, and the radial artery at the midpoint between the radial styloid process and elbow crease.

A qualified vascular sonographer who did not acquire the images performs all measurements offline using OsiriX MD for Lumify images and VxView for VxWave images. Random dataset identifiers conceal participant identity, pairing and repeat status. Measurements from the corresponding other-system dataset are unavailable during review. Imaging-system identity is not concealed by the use of separate software platforms.

The first 20 consecutive participants after Participant ID 030 who complete comparator acquisition undergo one repeat comparator scan after probe and gel removal and at least two minutes of rest. The first comparator acquisition remains the reference for primary agreement analysis; repeat acquisition is used only for reference-pathway repeatability.

Enrollment stops upon reaching either 50 participants with successful unilateral scans in the per-protocol set or 85 participants in the full analysis set. The first unilateral visit supplies the primary participant record. Optional contralateral-arm visits provide exploratory observations. No routine follow-up visit is scheduled; any adverse event is followed until resolution or 60 days, whichever occurs first.

Participants may provide consent and enroll at Prince of Wales Private or remotely. All ultrasound scanning and study imaging data acquisition are performed at Vexev Pty Ltd, Suite 501, 78 Kippax Street, Surry Hills NSW 2010. The Prince of Wales Private location is used for recruitment, consent and enrollment only; no scanning or imaging data acquisition takes place there.

Typ studiów

Interwencyjne

Zapisy (Szacowany)

85

Faza

  • Nie dotyczy

Kontakty i lokalizacje

Ta sekcja zawiera dane kontaktowe osób prowadzących badanie oraz informacje o tym, gdzie badanie jest przeprowadzane.

Kontakt w sprawie studiów

Lokalizacje studiów

    • New South Wales
      • Randwick, New South Wales, Australia, 2031
        • Prince of Wales Private, A/Prof Shannon Thomas's Rooms (Recruitment and Enrollment Only)
        • Kontakt:
      • Surry Hills, New South Wales, Australia, 2010
        • Vexev Pty Ltd
        • Kontakt:

Kryteria uczestnictwa

Badacze szukają osób, które pasują do określonego opisu, zwanego kryteriami kwalifikacyjnymi. Niektóre przykłady tych kryteriów to ogólny stan zdrowia danej osoby lub wcześniejsze leczenie.

Kryteria kwalifikacji

Wiek uprawniający do nauki

21 lat i starsze (Dorosły, Starszy dorosły)

Akceptuje zdrowych ochotników

Tak

Płeć kwalifikująca się do nauki

Wszystko

Opis

Inclusion Criteria:

  • Age 21 years or older and able to provide written informed consent.
  • Complete upper limb(s).

Exclusion Criteria:

  • Unable to provide informed consent.
  • Unable or unwilling to place the limb onto the VxWave scanning bed.
  • Infection risk to site staff and/or other study participants.
  • Open or healing wound on the study limb.
  • Known abnormal upper-limb vascular anatomy that would make scanning at the protocol discrete locations infeasible.
  • Known allergy to parabens present in standard ultrasound gels.
  • Any other reason at the discretion of the Principal Investigator.
  • Previous upper-limb vascular surgery.
  • Highly dependent on medical care.
  • Cognitive impairment or intellectual disability.

Vascular-anatomy and prior-surgery exclusions are assessed using self-reported history; review of medical records is not required for this assessment.

Plan studiów

Ta sekcja zawiera szczegółowe informacje na temat planu badania, w tym sposób zaprojektowania badania i jego pomiary.

Jak projektuje się badanie?

Szczegóły projektu

  • Główny cel: Inny
  • Przydział: Nie dotyczy
  • Model interwencyjny: Zadanie dla jednej grupy
  • Maskowanie: Brak (otwarta etykieta)

Broń i interwencje

Grupa uczestników / Arm
Interwencja / Leczenie
Eksperymentalny: VxWave and Comparator Ultrasound

All participants undergo VxWave scanning followed by Philips Lumify scanning of the same arm during one study visit. The first 20 consecutive participants after Participant ID 030 who complete comparator acquisition also undergo a repeat Lumify scan after probe lift-off and at least two minutes of rest.

Robotically controlled acquisition of duplex B-mode and Doppler ultrasound data of the upper-limb vasculature, excluding the hand. The participant rests the limb on the scan bed while the probe moves beneath it. Images are measured offline using VxView. VxWave scanning occurs before the comparator scan.

Qualified vascular-sonographer acquisition of ultrasound data from the same upper-limb vascular locations after VxWave scanning. Images are measured offline using OsiriX MD. The specified repeatability subset undergoes a separate repeat comparator acquisition after probe lift-off and at least two minutes of rest.

Co mierzy badanie?

Podstawowe miary wyniku

Miara wyniku
Opis środka
Ramy czasowe
Inter-System Agreement in Arterial Diameter
Ramy czasowe: During the first study visit (Day 1; approximately 2 hours, or 2 hours 15 minutes with repeat comparator scanning).

Mean bias and 95% limits of agreement for VxWave minus comparator arterial diameter in millimetres at three pre-specified brachial/radial artery locations. Each location uses the mean of three diameter measurements. Multilevel Bland-Altman analysis accounts for measurements within participants, with 95% confidence intervals for bias and limits of agreement. The +/-0.5 mm margin is a descriptive benchmark and does not define a binary study-success criterion. Only diagnostic-quality measurements are included in agreement analysis.

During the first study visit (Day 1; approximately 2 hours, or 2 hours 15 minutes with repeat comparator scanning).
Inter-System Agreement in Peak Systolic Velocity
Ramy czasowe: During the first study visit (Day 1; approximately 2 hours, or 2 hours 15 minutes with repeat comparator scanning).

Mean percentage bias and 95% limits of agreement in symmetric relative percentage differences between VxWave and comparator peak systolic velocity at the three pre-specified brachial/radial artery locations. Mean of three representative peak systolic velocity measurements per location. Multilevel Bland-Altman analysis accounts for measurements within participants, with 95% confidence intervals for bias and limits of agreement. Absolute-scale agreement in cm/s is a sensitivity analysis. No PSV acceptance criterion is specified. Only diagnostic-quality measurements are included.

During the first study visit (Day 1; approximately 2 hours, or 2 hours 15 minutes with repeat comparator scanning).

Miary wyników drugorzędnych

Miara wyniku
Opis środka
Ramy czasowe
Successful VxWave Scan Completion
Ramy czasowe: During the VxWave scan at the first study visit (Day 1).

Percentage of participants for whom VxWave completes the peripheral vascular imaging examination, with scan data judged by the reporting sonographer to be of diagnostic quality for measurement and able to confirm measurements. Reasons for failure include inability to perform both B-mode and Doppler measurements at two of the three discrete locations, or failure to complete scan data acquisition within a reasonable time (less than 55 minutes).

During the VxWave scan at the first study visit (Day 1).
Time Required to Complete VxWave Scanning
Ramy czasowe: During the VxWave scan at the first study visit (Day 1).

Elapsed time in minutes from initiation of the first acquisition run on the VxWave console to scan status complete on the final acquisition run, including time between runs. A scan may contain more than one acquisition run, including restarts after participant repositioning.

During the VxWave scan at the first study visit (Day 1).
Participant Comfort and Satisfaction With VxWave Scanning
Ramy czasowe: Immediately after the VxWave scan during the first study visit (Day 1).

Four questionnaire items assess overall comfort, satisfaction with scanning time, satisfaction with audible noise and overall satisfaction. Each item has five ordered response categories: Excellent, Very good, Good, Fair and Poor, with Excellent representing the most favorable response. Ordinal responses will be summarised using median/interquartile range or proportions. No composite score is specified in the protocol or supplied assessment form.

Immediately after the VxWave scan during the first study visit (Day 1).
Repeatability of Comparator Arterial Diameter Measurements
Ramy czasowe: During the first study visit (Day 1); repeat comparator acquisition follows probe lift-off and at least two minutes of rest.

For the first 20 consecutive participants after Participant ID 030 who complete comparator acquisition, assess mean difference (bias), 95% limits of agreement and repeatability coefficient between first and repeat comparator arterial diameter measurements in millimetres at each pre-specified location. Multilevel Bland-Altman analysis accounts for measurements within participants, with 95% confidence intervals for bias and limits of agreement. The first comparator acquisition remains the reference for the primary endpoint; repeat acquisition is used for this secondary endpoint only.

During the first study visit (Day 1); repeat comparator acquisition follows probe lift-off and at least two minutes of rest.
Repeatability of Comparator Peak Systolic Velocity Measurements
Ramy czasowe: During the first study visit (Day 1); repeat comparator acquisition follows probe lift-off and at least two minutes of rest.

For the same 20-participant repeatability cohort, assess mean difference (bias), 95% limits of agreement and repeatability coefficient between first and repeat comparator peak systolic velocity measurements, expressed as symmetric relative percentage differences, at each pre-specified location. Multilevel Bland-Altman analysis accounts for measurements within participants, with 95% confidence intervals. This descriptive endpoint characterises reference-pathway repeatability and does not define an acceptance test.

During the first study visit (Day 1); repeat comparator acquisition follows probe lift-off and at least two minutes of rest.

Inne miary wyników

Miara wyniku
Opis środka
Ramy czasowe
Percentage of Scanned Participants With at Least One Device Deficiency
Ramy czasowe: During the study scanning visit (Day 1).

100 multiplied by the number of unique scanned participants whose scan is associated with at least one VxWave device deficiency, divided by the total number of unique participants who undergo a scan. Include attempted scans regardless of successful completion or diagnostic image quality. Each participant is counted once, even if more than one deficiency or scan occurs. Device deficiencies include those identified before scan completion.

During the study scanning visit (Day 1).
Percentage of Scanned Participants With at Least One Adverse Event
Ramy czasowe: During the study visit (Day 1), with any adverse event followed until resolution or 60 days, whichever occurs first.

100 multiplied by the number of unique scanned participants who experience at least one adverse event (AE), divided by the total number of unique participants who undergo a scan. AEs are counted regardless of their relationship to the device or study procedure. Include attempted scans regardless of successful completion. Each participant is counted once, even if multiple AEs or scans occur. Device/procedure-related AEs are included in this overall AE measure and are also reported separately as adverse device effects.

During the study visit (Day 1), with any adverse event followed until resolution or 60 days, whichever occurs first.
Percentage of Scanned Participants With at Least One Adverse Device Effect
Ramy czasowe: During the study visit (Day 1), with any adverse event followed until resolution or 60 days, whichever occurs first.

100 multiplied by the number of unique scanned participants who experience at least one adverse device effect (ADE), divided by the total number of unique participants who undergo a scan. Per the protocol, an ADE is an AE related to the VxWave Ultrasound Imaging System or study procedure. Include attempted scans regardless of successful completion. Each participant is counted once, even if multiple ADEs or scans occur. ADEs are a subset of all AEs; the overall AE percentage and ADE percentage must not be added together.

During the study visit (Day 1), with any adverse event followed until resolution or 60 days, whichever occurs first.

Współpracownicy i badacze

Tutaj znajdziesz osoby i organizacje zaangażowane w to badanie.

Sponsor

Śledczy

  • Główny śledczy: Tam Nguyen, Vexev Pty Ltd

Daty zapisu na studia

Daty te śledzą postęp w przesyłaniu rekordów badań i podsumowań wyników do ClinicalTrials.gov. Zapisy badań i zgłoszone wyniki są przeglądane przez National Library of Medicine (NLM), aby upewnić się, że spełniają określone standardy kontroli jakości, zanim zostaną opublikowane na publicznej stronie internetowej.

Główne daty studiów

Rozpoczęcie studiów (Szacowany)

15 listopada 2026

Zakończenie podstawowe (Szacowany)

15 stycznia 2027

Ukończenie studiów (Szacowany)

20 stycznia 2027

Daty rejestracji na studia

Pierwszy przesłany

29 października 2026

Pierwszy przesłany, który spełnia kryteria kontroli jakości

29 października 2026

Pierwszy wysłany (Rzeczywisty)

4 listopada 2026

Aktualizacje rekordów badań

Ostatnia wysłana aktualizacja (Rzeczywisty)

4 listopada 2026

Ostatnia przesłana aktualizacja, która spełniała kryteria kontroli jakości

29 października 2026

Ostatnia weryfikacja

1 października 2026

Więcej informacji

Terminy związane z tym badaniem

Inne numery identyfikacyjne badania

  • CIP-2

Plan dla danych uczestnika indywidualnego (IPD)

Planujesz udostępniać dane poszczególnych uczestników (IPD)?

TAK

Opis planu IPD

Individual participant data will be shared on request.

Kryteria dostępu do udostępniania IPD

On request.

Informacje o lekach i urządzeniach, dokumenty badawcze

Bada produkt leczniczy regulowany przez amerykańską FDA

Nie

Bada produkt urządzenia regulowany przez amerykańską FDA

Nie

Te informacje zostały pobrane bezpośrednio ze strony internetowej clinicaltrials.gov bez żadnych zmian. Jeśli chcesz zmienić, usunąć lub zaktualizować dane swojego badania, skontaktuj się z register@clinicaltrials.gov. Gdy tylko zmiana zostanie wprowadzona na stronie clinicaltrials.gov, zostanie ona automatycznie zaktualizowana również na naszej stronie internetowej .

Subskrybuj